Questioning Medicare’s Coverage Decisions

With Medicare’s recent decisions to cover the $93,000 Provenge for certain forms of advanced prostate cancer and Avastin for breast-cancer patients (even if the FDA follows the advice of its outside advisory committee and revokes that drug’s approval), Merill Goozner wonders, “How much should you, your insurer or the government pay for an extra month of life? How much is an extra month of hope worth, even if doesn’t extend life?”